Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 iptacopan versus placebo study in complement 3 glomerulopathy
NL-OMON56053Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Iptacopan in Complement 3 glomerulopathy (C3G) (4 arms), sponsored by Novartis. Primary endpoints: Log-transformed ratio to baseline in UPCR at 6 months, Change from baseline in log-transformed UPCR at 12 months and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NL-OMON56053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56053.